Regulation - Pricing, Biotechnology

Filter

Current filters:

PricingBiotechnology

Popular Filters

1 to 25 of 78 results

UK doctors call for approval of off-label use of Avastin for wet-AMD

UK doctors call for approval of off-label use of Avastin for wet-AMD

25-02-2015

Doctors in the UK are calling on health ministers and NHS England to intervene to make Swiss pharma giant…

AvastinBiotechnologyHealthcareLucentisNovartisOphthalmicsPricingRegulationRocheUK

IQWiG says Octapharma provided no suitable data on Nuwiq to show added benefit

IQWiG says Octapharma provided no suitable data on Nuwiq to show added benefit

20-02-2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined data on independent…

BiotechnologyGermanyHematologyNuwiqOctapharmaPricingRegulation

NICE final draft guidance does not recommend pomalidomide for blood cancer

NICE final draft guidance does not recommend pomalidomide for blood cancer

13-02-2015

The England medical costs watchdog the National Institute for Health and Care excellence (NICE) has issued…

BiotechnologyCelgene CorpImnovidOncologypomalidomidePricingRegulationUK

First UK NICE highly specialized technologies guidance recommends Soliris

First UK NICE highly specialized technologies guidance recommends Soliris

28-01-2015

England’s health costs watchdog the National Institute for Health and care Excellence has today issued…

Alexion PharmaceuticalsBiotechnologyHematologyPricingRare diseasesRegulationSolarisUK

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

16-01-2015

In final draft guidance issued today, England health costs watchdog the National Institute for Health…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioPricingRegulationSovaldiUK

Cost to NHS of Provenge too high to be recommended, says NICE

13-01-2015

England’s health care cost watchdog the National Institute for Health and Care Excellence (NICE) has…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

NICE opens consultation on Millennium’s Crohn’s drug Entyvio

23-12-2014

In draft guidance issued today, UK health costs watchdog the National Institute for Health and Care Excellence…

BiotechnologyEntyvioGastro-intestinalsMillennium PharmaceuticalsPricingRegulationTakeda PharmaceuticalUK

NICE now proposes to recommend Stelara for psoriatic arthritis

NICE now proposes to recommend Stelara for psoriatic arthritis

09-12-2014

UK health cost watchdog, the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsBiotechnologyInflammatory diseasesJanssenJohnson & JohnsonPricingRegulationStelaraUK

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

27-11-2014

The UK National Institute for Health and Care Excellence (NICE) has today issued final draft guidance…

Alexion PharmaceuticalsBiotechnologyPricingRare diseasesRegulationSolirisUK

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

04-09-2014

A drug to treat a very rare blood disorder affecting around 200 people in England has been recommended…

Alexion PharmaceuticalsBiotechnologyHematologyPricingRare diseasesRegulationSolirisUK

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

15-08-2014

In further draft guidance published today, UK drugs watchdog the National Institute for Health and Care…

Anti-viralsBiotechnologyGilead SciencesHepatitis CPricingRegulationRibavirinSovaldiUK

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

08-08-2014

In its early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

Biogen IdecBiotechnologyGermanyMSNeurologicalPricingRegulationTecfidera

Chiesi and uniQure delay Glybera launch to add data

Chiesi and uniQure delay Glybera launch to add data

04-08-2014

Netherlands-based venture capital backed human gene therapy firm uniQure and privately-held Italian drugmaker…

BiotechnologyChiesi FarmaceuticiEuropeGlyberaOrphan disease lipoprotein lipase deficiencyPricingRare diseasesRegulationuniQure

NICE issues positive draft FAD guidance on Tecfidera

NICE issues positive draft FAD guidance on Tecfidera

11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalPricingRegulationTecfideraUK

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

16-06-2014

In draft recommendations published today, UK health care watchdog the National Institute for Health and…

Anti-viralsBiotechnologyGilead SciencesPricingRegulationSovaldiUK

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

09-06-2014

There was good news for US antivirals major Gilead Sciences, when France’s health technology assessment…

Anti-viralsBiotechnologyFranceGilead SciencesPricingRegulationSovaldi

Genzyme gains UK NICE backing for second MS drug Lemtrada

Genzyme gains UK NICE backing for second MS drug Lemtrada

28-05-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

AubagioBiotechnologyGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

1 to 25 of 78 results

COMPANY SPOTLIGHT

Menarini

Back to top